MannKind Reports 2025 Financial Results with Strong Sales Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy MNKD?
Source: Benzinga
- Earnings Highlights: MannKind reported adjusted earnings per share of one cent for Q4 2025, aligning with market expectations, while quarterly sales reached $111.955 million, surpassing the Street's forecast of $97.604 million, indicating robust sales performance.
- Revenue Growth Drivers: The company noted that total revenues for Q4 and the full year 2025 increased due to higher royalties, collaborations, and commercial product sales, with the addition of Furoscix significantly boosting their cardiometabolic franchise, while Afrezza and UT-related revenues continue to show sustained growth, reflecting a positive impact from product diversification.
- Cash Position: MannKind exited the quarter with cash and equivalents totaling $74.882 million, ensuring financial flexibility for future operations and supporting ongoing R&D and market expansion initiatives.
- Market Technical Analysis: The stock is currently trading at $3.26, 9.8% below its 20-day simple moving average, indicating a bearish trend in the short term; however, with an RSI of 44.45, the market is in neutral territory, suggesting that investors should approach future market fluctuations with caution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MNKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MNKD
Wall Street analysts forecast MNKD stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.610
Low
7.50
Averages
9.25
High
11.00
Current: 2.610
Low
7.50
Averages
9.25
High
11.00
About MNKD
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MannKind Presents New Data on Afrezza at Diabetes Conference
- Clinical Data Presentation: MannKind will showcase clinical and real-world data on Afrezza at the 2026 Advanced Technologies & Treatments for Diabetes Conference, including inhaled insulin use in children and adolescents, which is expected to enhance understanding of post-prandial glucose management and strengthen its market position in diabetes treatment.
- FDA Review Progress: The FDA accepted a supplemental Biologics License Application for Afrezza in children and adolescents aged 4-17 in October 2025, with a target action date of May 29, 2026; if approved, it would be the first needle-free insulin option in over 100 years, potentially transforming pediatric diabetes management.
- Research Findings Sharing: The conference will feature two oral presentations comparing the efficacy of Afrezza across various clinical studies and highlighting data from the INHALE-1 study, focusing on dosing and titration patterns of inhaled insulin in youth, which could lead to improved clinical practices.
- Industry Engagement Opportunity: MannKind executives noted that the ATTD conference serves as a key platform for advancing clinicians' perspectives on meal-time insulin use, and engaging with the global diabetes community will help elevate Afrezza's market awareness and acceptance.
See More
MannKind CEO Acquires 100,000 Shares
- Executive Purchase: MannKind CEO Michael Castagna purchased 100,000 shares on March 10, 2026, at $2.59 per share, increasing his direct ownership to 2.58 million shares, indicating strong confidence in the company's future.
- Stock Price Surge: Following the announcement of Castagna's purchase, MannKind's stock rose by 7.7%, reflecting a positive market reaction to insider buying, which may bolster investor confidence in the company's outlook.
- Future Revenue Outlook: MannKind projects a revenue run rate of $450 million for 2026 while preparing for the pediatric launch of Afrezza, highlighting several key product catalysts that suggest significant growth potential in the market.
- Earnings Report Impact: Despite missing expectations in its Q4 2025 earnings report, which led to a 52-week low in stock price, the executive purchase and optimistic revenue forecasts may create new investment opportunities for the company.
See More
MannKind Corp Reports Record Q4 Revenue and Strategic Developments
- Record Quarterly Revenue: MannKind Corp reported a record quarterly revenue of $112 million in Q4 2025, reflecting a 46% year-over-year increase, indicating strong market performance and sustained growth potential.
- Acquisition Enhances Product Line: The company completed the acquisition of SC Pharmaceuticals, which enhances its cardio metabolic franchise and is expected to drive future revenue growth and market competitiveness.
- Diversified Product Portfolio: MannKind currently has four FDA-approved products, reducing dependency on a single revenue stream, thereby enhancing the company's financial stability and risk resilience.
- Future Revenue Outlook: The company anticipates a revenue run rate exceeding $450 million in 2026, primarily driven by strategic investments and product launches, demonstrating its proactive positioning and growth confidence in the market.
See More
MannKind Corporation Settles Remaining Convertible Notes
- Debt Settlement Completed: MannKind Corporation successfully settled the remaining $36.3 million of its 2.50% convertible senior notes, all of which were tendered for conversion prior to the March 1, 2026 maturity date, demonstrating effective financial management and optimization of its debt structure.
- Cash and Stock Payment: The settlement involved $35.5 million in cash and the issuance of 569,023 shares of MannKind common stock, indicating robust liquidity management while providing additional equity value to shareholders.
- Focus on Chronic Disease Treatment: MannKind is dedicated to transforming chronic disease care through innovative, patient-centric solutions, with a focus on cardiometabolic and orphan lung diseases, highlighting its strategic positioning in addressing serious unmet medical needs.
- Expertise in Drug-Device Combinations: With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life, further solidifying its competitive advantage in the biopharmaceutical industry.
See More
MannKind Reports 2025 Financial Results with Strong Sales Growth
- Earnings Highlights: MannKind reported adjusted earnings per share of one cent for Q4 2025, aligning with market expectations, while quarterly sales reached $111.955 million, surpassing the Street's forecast of $97.604 million, indicating robust sales performance.
- Revenue Growth Drivers: The company noted that total revenues for Q4 and the full year 2025 increased due to higher royalties, collaborations, and commercial product sales, with the addition of Furoscix significantly boosting their cardiometabolic franchise, while Afrezza and UT-related revenues continue to show sustained growth, reflecting a positive impact from product diversification.
- Cash Position: MannKind exited the quarter with cash and equivalents totaling $74.882 million, ensuring financial flexibility for future operations and supporting ongoing R&D and market expansion initiatives.
- Market Technical Analysis: The stock is currently trading at $3.26, 9.8% below its 20-day simple moving average, indicating a bearish trend in the short term; however, with an RSI of 44.45, the market is in neutral territory, suggesting that investors should approach future market fluctuations with caution.
See More
MannKind's Earnings Miss Expectations, Stock Drops
- Earnings Performance: MannKind reported its Q4 and full-year 2025 results, showing a 46% year-over-year revenue increase to nearly $112 million, although this figure includes $22.9 million from Furoscix sales, indicating positive progress in drug integration.
- Net Income Decline: The company's net income fell to just over $1.5 million ($0.01 per share), a significant drop from nearly $23 million last year, missing the average analyst estimate of $0.02 per share for non-GAAP profitability, reflecting pressure from rising costs.
- Cost Impact: Increased cost of goods sold, primarily due to the integration of Furoscix and higher R&D expenses, significantly impacted profitability, despite revenue exceeding the market expectation of $97.9 million.
- Overreaction in Market: Although the stock price dropped over 7% due to the earnings report, analysts believe that the addition of Furoscix and the company's strong pipeline make the current stock price attractive, suggesting an overreaction from investors.
See More
MannKind Presents New Data on Afrezza at Diabetes Conference
- Clinical Data Presentation: MannKind will showcase clinical and real-world data on Afrezza at the 2026 Advanced Technologies & Treatments for Diabetes Conference, including inhaled insulin use in children and adolescents, which is expected to enhance understanding of post-prandial glucose management and strengthen its market position in diabetes treatment.
- FDA Review Progress: The FDA accepted a supplemental Biologics License Application for Afrezza in children and adolescents aged 4-17 in October 2025, with a target action date of May 29, 2026; if approved, it would be the first needle-free insulin option in over 100 years, potentially transforming pediatric diabetes management.
- Research Findings Sharing: The conference will feature two oral presentations comparing the efficacy of Afrezza across various clinical studies and highlighting data from the INHALE-1 study, focusing on dosing and titration patterns of inhaled insulin in youth, which could lead to improved clinical practices.
- Industry Engagement Opportunity: MannKind executives noted that the ATTD conference serves as a key platform for advancing clinicians' perspectives on meal-time insulin use, and engaging with the global diabetes community will help elevate Afrezza's market awareness and acceptance.
See More
MannKind CEO Acquires 100,000 Shares
- Executive Purchase: MannKind CEO Michael Castagna purchased 100,000 shares on March 10, 2026, at $2.59 per share, increasing his direct ownership to 2.58 million shares, indicating strong confidence in the company's future.
- Stock Price Surge: Following the announcement of Castagna's purchase, MannKind's stock rose by 7.7%, reflecting a positive market reaction to insider buying, which may bolster investor confidence in the company's outlook.
- Future Revenue Outlook: MannKind projects a revenue run rate of $450 million for 2026 while preparing for the pediatric launch of Afrezza, highlighting several key product catalysts that suggest significant growth potential in the market.
- Earnings Report Impact: Despite missing expectations in its Q4 2025 earnings report, which led to a 52-week low in stock price, the executive purchase and optimistic revenue forecasts may create new investment opportunities for the company.
See More
MannKind Corp Reports Record Q4 Revenue and Strategic Developments
- Record Quarterly Revenue: MannKind Corp reported a record quarterly revenue of $112 million in Q4 2025, reflecting a 46% year-over-year increase, indicating strong market performance and sustained growth potential.
- Acquisition Enhances Product Line: The company completed the acquisition of SC Pharmaceuticals, which enhances its cardio metabolic franchise and is expected to drive future revenue growth and market competitiveness.
- Diversified Product Portfolio: MannKind currently has four FDA-approved products, reducing dependency on a single revenue stream, thereby enhancing the company's financial stability and risk resilience.
- Future Revenue Outlook: The company anticipates a revenue run rate exceeding $450 million in 2026, primarily driven by strategic investments and product launches, demonstrating its proactive positioning and growth confidence in the market.
See More
MannKind Corporation Settles Remaining Convertible Notes
- Debt Settlement Completed: MannKind Corporation successfully settled the remaining $36.3 million of its 2.50% convertible senior notes, all of which were tendered for conversion prior to the March 1, 2026 maturity date, demonstrating effective financial management and optimization of its debt structure.
- Cash and Stock Payment: The settlement involved $35.5 million in cash and the issuance of 569,023 shares of MannKind common stock, indicating robust liquidity management while providing additional equity value to shareholders.
- Focus on Chronic Disease Treatment: MannKind is dedicated to transforming chronic disease care through innovative, patient-centric solutions, with a focus on cardiometabolic and orphan lung diseases, highlighting its strategic positioning in addressing serious unmet medical needs.
- Expertise in Drug-Device Combinations: With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life, further solidifying its competitive advantage in the biopharmaceutical industry.
See More
MannKind Reports 2025 Financial Results with Strong Sales Growth
- Earnings Highlights: MannKind reported adjusted earnings per share of one cent for Q4 2025, aligning with market expectations, while quarterly sales reached $111.955 million, surpassing the Street's forecast of $97.604 million, indicating robust sales performance.
- Revenue Growth Drivers: The company noted that total revenues for Q4 and the full year 2025 increased due to higher royalties, collaborations, and commercial product sales, with the addition of Furoscix significantly boosting their cardiometabolic franchise, while Afrezza and UT-related revenues continue to show sustained growth, reflecting a positive impact from product diversification.
- Cash Position: MannKind exited the quarter with cash and equivalents totaling $74.882 million, ensuring financial flexibility for future operations and supporting ongoing R&D and market expansion initiatives.
- Market Technical Analysis: The stock is currently trading at $3.26, 9.8% below its 20-day simple moving average, indicating a bearish trend in the short term; however, with an RSI of 44.45, the market is in neutral territory, suggesting that investors should approach future market fluctuations with caution.
See More
MannKind's Earnings Miss Expectations, Stock Drops
- Earnings Performance: MannKind reported its Q4 and full-year 2025 results, showing a 46% year-over-year revenue increase to nearly $112 million, although this figure includes $22.9 million from Furoscix sales, indicating positive progress in drug integration.
- Net Income Decline: The company's net income fell to just over $1.5 million ($0.01 per share), a significant drop from nearly $23 million last year, missing the average analyst estimate of $0.02 per share for non-GAAP profitability, reflecting pressure from rising costs.
- Cost Impact: Increased cost of goods sold, primarily due to the integration of Furoscix and higher R&D expenses, significantly impacted profitability, despite revenue exceeding the market expectation of $97.9 million.
- Overreaction in Market: Although the stock price dropped over 7% due to the earnings report, analysts believe that the addition of Furoscix and the company's strong pipeline make the current stock price attractive, suggesting an overreaction from investors.
See More
